188 related articles for article (PubMed ID: 35236677)
1. Multidisciplinary approach to anti-MDA5 antibody-positive dermatomyositis associated with rapidly progressive interstitial lung disease.
Witkowska AB; Cowley S; Dempsey P; Stack J
BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35236677
[TBL] [Abstract][Full Text] [Related]
2. Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review.
Yeung TW; Cheong KN; Lau YL; Tse KN
Pediatr Rheumatol Online J; 2021 Jun; 19(1):103. PubMed ID: 34193210
[TBL] [Abstract][Full Text] [Related]
3. Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases.
Mehta AA; Paul T; Cb M; Haridas N
BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33910791
[TBL] [Abstract][Full Text] [Related]
4. Anti-MDA5 antibody-associated clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease.
Horino T; Inotani S; Nakajima K; Ohnishi H; Komori M; Terada Y
Joint Bone Spine; 2022 Nov; 89(6):105456. PubMed ID: 36108903
[No Abstract] [Full Text] [Related]
5. [Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review].
Hou J; Zhou ZX; Li JG; Xu YJ; Ding YC
Zhonghua Er Ke Za Zhi; 2019 Dec; 57(12):928-933. PubMed ID: 31795559
[No Abstract] [Full Text] [Related]
6. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
[TBL] [Abstract][Full Text] [Related]
7. Anti-MDA5 positive dermatomyositis complicated with rapidly progressive interstitial lung disease - a case report.
De Backer E; Gremonprez F; Brusselle G; Depuydt P; Van Dorpe J; Van Haverbeke C; Goeminne PC; Derom E
Acta Clin Belg; 2018 Dec; 73(6):413-417. PubMed ID: 29287518
[TBL] [Abstract][Full Text] [Related]
8. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H
Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789
[TBL] [Abstract][Full Text] [Related]
9. A case of autoimmune pulmonary alveolar proteinosis during the course of treatment of rapidly progressive interstitial pneumonia associated with anti-MDA5 antibody-positive dermatomyositis.
Yatomi M; Akasaka K; Sato S; Chida M; Kanbe M; Sawada H; Yokota I; Wakamatsu I; Muto S; Sato M; Yamaguchi K; Miura Y; Tsurumaki H; Sakurai R; Hara K; Koga Y; Sunaga N; Yamakawa H; Matsushima H; Yamazaki S; Endo Y; Motegi SI; Hisada T; Maeno T
BMC Pulm Med; 2024 Apr; 24(1):170. PubMed ID: 38589870
[TBL] [Abstract][Full Text] [Related]
10. [Clinically amyopathic dermatomyositis : a rare entity associated with acute and severe interstitial lung disease].
Debrus C; Calmes D; Von Frenckell C; Duysinx B; Cataldo D; Corhay JL; Louis R; Guiot J
Rev Med Liege; 2023 Jul; 78(7-8):441-447. PubMed ID: 37560958
[TBL] [Abstract][Full Text] [Related]
11. Aggressive multi-combination therapy for anti-MDA5 antibody-positive dermatomyositis-rapidly progressive interstitial lung disease.
Hata K; Kotani T; Matsuda S; Fujiki Y; Suzuka T; Kiboshi T; Wada Y; Shiba H; Shoda T; Kagitani M; Takeuchi T
Int J Rheum Dis; 2024 Jan; 27(1):e14999. PubMed ID: 38063858
[TBL] [Abstract][Full Text] [Related]
12. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
Koichi Y; Aya Y; Megumi U; Shunichi K; Masafumi S; Hiroaki M; Masahiko K; Shinsuke K; Manabu U; Kenichiro H; Fumiaki A; Nozomi A; Toshitaka M; Masayoshi Y; Chikako K; Yoshinao M; Tatsuo S; Masahiko K
Mod Rheumatol; 2017 May; 27(3):536-540. PubMed ID: 25698373
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
[TBL] [Abstract][Full Text] [Related]
14. [Risk Factors of Rapidly Progressive Interstitial Lung Disease in Patients With Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis].
Han YY; Jiang T; Zhang ZH; Li W; Jiang YD; Lu CC; Fei Y; Chen B
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 54(2):422-425. PubMed ID: 36949709
[TBL] [Abstract][Full Text] [Related]
15. Lung transplantation for anti-MDA5-positive dermatomyositis-associated rapid progressive interstitial lung disease: report of two cases and review of the literature.
Lian QY; Chen A; Zhang JH; Xu X; Huang DX; Luo Q; He JX; Ju CR
Clin Rheumatol; 2023 Mar; 42(3):941-947. PubMed ID: 36441397
[TBL] [Abstract][Full Text] [Related]
16. A fatal interstitial lung disease in an anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody negative patient with juvenile dermatomyositis.
Yeşilbaş O; Yıldız M; Yozgat CY; Tahaoğlu I; Yazan H; Çakır E; Adrovic A; Şahin S; Barut K; Kasapçopur Ö
Turk J Pediatr; 2021; 63(5):903-908. PubMed ID: 34738372
[TBL] [Abstract][Full Text] [Related]
17. Anti-melanoma Differentiation-associated Gene 5 Antibody-positive Dermatomyositis Presenting as Refractory Gingivitis at the First Clinical Manifestation.
Kawakami E; Uchida T; Iwamoto N; Hara K; Egashira K; Kawakami A
Intern Med; 2024 Jan; 63(1):131-134. PubMed ID: 37197957
[TBL] [Abstract][Full Text] [Related]
18. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
[TBL] [Abstract][Full Text] [Related]
19. Concurrent Treatment With Rituximab and Plasma Exchange for Rapidly Progressive Interstitial Lung Disease Complicating Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis.
Shimizu M; Inoue N; Takeda Y; Kidouchi K; Fujita N; Fujiki T; Takasaki A; Adachi Y; Wada T
J Clin Rheumatol; 2021 Dec; 27(8S):S798-S799. PubMed ID: 35073639
[No Abstract] [Full Text] [Related]
20. Treatment of myopathy and cutaneous ulcers in anti-MDA5-positive dermatomyositis with triple therapy.
Peringeth G; Abbi B; Mahmood S
BMJ Case Rep; 2024 Mar; 17(3):. PubMed ID: 38514155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
